Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Receives $205.67 Average PT from Analysts

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) has been assigned an average rating of “Moderate Buy” from the eighteen analysts that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and fourteen have issued a buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $205.6667.

Several analysts have commented on the stock. Truist Financial increased their price target on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research report on Monday, January 12th. Piper Sandler reissued an “overweight” rating and set a $219.00 target price (up previously from $147.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, December 10th. Robert W. Baird raised their target price on shares of Jazz Pharmaceuticals from $160.00 to $209.00 and gave the company an “outperform” rating in a research note on Tuesday, November 18th. Morgan Stanley reaffirmed an “overweight” rating and set a $225.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, January 8th. Finally, Bank of America increased their price objective on Jazz Pharmaceuticals from $230.00 to $247.00 and gave the company a “buy” rating in a report on Tuesday, November 18th.

Jazz Pharmaceuticals Stock Down 0.3%

Shares of NASDAQ JAZZ opened at $165.00 on Friday. Jazz Pharmaceuticals has a 12-month low of $95.49 and a 12-month high of $182.99. The stock’s fifty day simple moving average is $167.72 and its two-hundred day simple moving average is $146.05. The stock has a market capitalization of $10.03 billion, a PE ratio of -27.18, a price-to-earnings-growth ratio of 0.89 and a beta of 0.26. The company has a current ratio of 1.65, a quick ratio of 1.44 and a debt-to-equity ratio of 1.09.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 77,500 shares of the firm’s stock in a transaction dated Wednesday, November 26th. The stock was sold at an average price of $177.81, for a total value of $13,780,275.00. Following the completion of the sale, the director owned 393,332 shares of the company’s stock, valued at approximately $69,938,362.92. This trade represents a 16.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Patricia Carr sold 4,660 shares of the company’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $171.20, for a total transaction of $797,792.00. Following the transaction, the chief accounting officer owned 7,012 shares in the company, valued at approximately $1,200,454.40. This trade represents a 39.92% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 123,791 shares of company stock valued at $21,991,850 in the last 90 days. 4.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Hilltop National Bank acquired a new position in Jazz Pharmaceuticals in the 4th quarter worth approximately $36,000. LRI Investments LLC acquired a new stake in Jazz Pharmaceuticals during the 4th quarter valued at approximately $38,000. Farther Finance Advisors LLC boosted its holdings in shares of Jazz Pharmaceuticals by 754.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock valued at $35,000 after acquiring an additional 234 shares during the last quarter. Leonteq Securities AG acquired a new stake in shares of Jazz Pharmaceuticals in the fourth quarter worth $50,000. Finally, GoalVest Advisory LLC purchased a new position in shares of Jazz Pharmaceuticals during the fourth quarter worth $51,000. 89.14% of the stock is owned by institutional investors and hedge funds.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.